Drug Discovery World

MARCH 10, 2023

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB’s antibody discovery expertise.

Research 246

Research Clinical Trials Clinical Development Trials 246

Advarra

MARCH 10, 2023

Having a one in four chance of developing sickle cell disease (SCD) is uniquely, and overwhelmingly, familiar to the African American population. Considered a rare disease, research in finding better therapies – and possibly even a cure – for SCD may be competing for funding with conditions impacting broader populations. SCD’s significant impact on African Americans also means it predominantly impacts a minority community historically underserved by clinical research.

Disease 98

Disease Clinical Trials Doctors Trials 98

Drug Channels

MARCH 8, 2023

Next week, Drug Channels Institute will release our 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 14th edition of our popular and comprehensive examination of the entire U.S. drug pricing, reimbursement, and dispensing system. The exhibit below—one of 241 in our new report—provides a first look at the 15 largest organizations, ranked by total U.S. prescription dispensing revenues for calendar year 2022.

Pharmacy 98

Pharmacy Specialty Pharmacies Marketing Drugs 98

Drug Patent Watch

MARCH 4, 2023

Annual Drug Patent Expirations for ORKAMBI Orkambi is a drug marketed by Vertex Pharms Inc and is included in two NDAs. It is available from one supplier. There are twenty… The post New patent for Vertex Pharms drug ORKAMBI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 97

Drugs Marketing 97

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Discovery World

MARCH 7, 2023

For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. The life sciences sector has traditionally outperformed others when it comes to attracting women to its workforce. In its ‘Women in Business 2022’ report, Grant Thornton reported that at 39%, the healthcare industry had the highest proportion of women in senior management out of the 15 industries surveyed. 1 However, this progress seems t

International 246

International Science Pharmaceuticals DNA 246

Eye on FDA

MARCH 5, 2023

In January we took a look at FDA Advisory Committees (AdComms) – FDA AdComms – When the Going Gets Tough – noting, among other things that there had not only been fewer meetings but also that it appeared that the outcomes were increasingly negative. Just to recap, for the entire year of 2022 there were only 14 meetings held to consider whether new medicines should be recommended for approval, a slight increase over the 10 the year before, but considerably lower fewer than 2018

FDA 72

FDA Vaccine Drugs Therapies 72

Drug Patent Watch

MARCH 4, 2023

Annual Drug Patent Expirations for SYMDEKO+%28COPACKAGED%29 Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier. There are… The post New patent for Vertex Pharms drug SYMDEKO (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 96

Drugs Marketing 96

Drug Discovery World

MARCH 10, 2023

News round-up for 6-10 March by DDW Digital Content Editor Diana Spencer. Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE). There have been several other announcements related to clinical trials in the last few days, including positive data from trials in severe influenza and biliary tract cancer, the launch of a study into an ADC treatment f

Clinical Trials 130

Clinical Trials Small Molecule Trials Drugs 130

NIOSH Science Blog: Drugs

MARCH 6, 2023

The construction sector includes a diverse population of workers exposed to many different types of hazards. An important way to prevent occupational illness and injury related to these hazards is by implementing the hierarchy of controls. Personal protective equipment (PPE) is the last control in the hierarchy, but PPE is particularly important when the other controls cannot sufficiently reduce or eliminate hazards.

66

66

Drug Channels

MARCH 6, 2023

Informa Connect’s Drug Pricing Transparency Congress May 16-17, 2023 in Washington, DC Drug Channels readers can save 10% with code 23DRCH10 www.informaconnect.com/drug-pricing-transparency Join Informa Connect on May 16-17, 2023 in Washington, DC at the Drug Pricing Transparency Congress to stay on the pulse of federal and state reporting requirements, policy initiatives and strategic best practices for compliance.

Compliance 98

Compliance Drugs Science Government 98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

FDA Law Blog: Biosimilars

MARCH 8, 2023

By Véronique Li, Senior Medical Device Regulation Expert — On March 17, 2023, enhancements to FDA’s electronic Medical Device Reporting (eMDR) system will go live. Manufacturers who submit reports via the FDA Electronic Submissions Gateway are being advised to update their systems by this time. Those who use eSubmitter will notice changes in the electronic 3500A template in the first week of March.

Packaging 59

Packaging FDA Production Regulations 59

Drug Discovery World

MARCH 10, 2023

African researchers are now able to access Collaborative Drug Discovery’s CDD Vault resource for neglected disease drug discovery collaborations. Collaborative Drug Discovery (CDD), a scientific informatics company that provides data management and analysis solutions, is offering free subscriptions to CDD Vault for select academic teams of scientists in Africa who are developing new drugs to combat neglected tropical diseases.

Organic Chemistry 130

Organic Chemistry Drugs Disease Research 130

Drug Patent Watch

MARCH 10, 2023

Annual Drug Patent Expirations for DYANAVEL+XR+10 Dyanavel Xr 10 is a drug marketed by Tris Pharma Inc and is included in one NDA. It is available from one supplier. There… The post New patent for Tris Pharma drug DYANAVEL XR 10 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Covalent Modifiers

MARCH 9, 2023

John C. Tran, Thomas Hunsaker, Christina Bell, Taylur P. Ma, Emily Chan, Pablo Saenz-Lopez Larrocha, Kelsey Homyk, Liling Liu, Hank La, Jialin Mao, Cecile C. de la Cruz, Kebing Yu, Maureen Beresini, William F. Forrest, Yang Xiao, Anne Jang, Natalia Samus, Nicholas Dupuis Stesco, Marija Mentinova, Stephane Parent, Gwenael Pottiez, Michael Schirm, Hans E.

Analytical Chemistry 52

Analytical Chemistry Drugs Research 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

FDA Law Blog: Biosimilars

MARCH 9, 2023

By John W.M. Claud & Douglas B. Farquhar — The annual ABA White Collar Crime Institute is a popular venue for prominent Department of Justice officials to make speeches announcing new policies. This year, Deputy Attorney General Lisa Monaco took the stage, and her speech included many of the well-known past hits from the corporate compliance chart.

Compliance 52

Compliance FDA Government Regulations 52

Drug Discovery World

MARCH 10, 2023

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In China, there were nearly 86,000 new cases of bladder cancer in 2020, and we are working with the NMPA to seek approval for enfortumab vedotin for patients wit

Pharmacokinetics 130

Pharmacokinetics Drugs Licensing Licensing 130

Drug Patent Watch

MARCH 10, 2023

Annual Drug Patent Expirations for DYANAVEL+XR Dyanavel Xr is a drug marketed by Tris Pharma Inc and is included in two NDAs. It is available from two suppliers. There are… The post New patent for Tris Pharma drug DYANAVEL XR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

New Drug Approvals

MARCH 9, 2023

Are you aware of any Chemical Database which offers one stop solution to the Sourcing, R&D and Business Development department? Explore Smartchem to Quickly find Suppliers (Procurement), Customers (BD) & Synthetic pathways (R&D) Is this the information you looking for? Evaluate SmartChem, lets schedule a demo. Try us once. You will use us for life.

52

52

Antidote

MARCH 9, 2023

Parkinson’s disease, a neurodegenerative brain disorder, impacts 10 million people across the world. Most commonly associated with tremors or shaking, it is a condition that significantly affects a person’s quality of life, and as of now, has no known cause. Individuals diagnosed with Parkinson’s are empowered to focus primarily on symptom management, which is typically done through medication and lifestyle changes.

Disease 52

Disease 52

Drug Discovery World

MARCH 9, 2023

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Dr Simon Fricker, who just last year was made Chief Development Officer of PepperBio to support the company’s next phase of growth and guide the strategic expansion of Pepper’s oncology pipeline.

Disease 130

Disease Drugs Science Drug Development 130

Drug Patent Watch

MARCH 10, 2023

Annual Drug Patent Expirations for DYANAVEL+XR+5 Dyanavel Xr 5 is a drug marketed by Tris Pharma Inc and is included in one NDA. It is available from one supplier. There… The post New patent for Tris Pharma drug DYANAVEL XR 5 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Cytel

MARCH 8, 2023

Real-world data has been increasingly used to answer questions related to the course, prognosis, and treatment of multiple sclerosis – yet each data source has its limitations, restricting the questions that can be addressed. Here is our solution.

Research 52

Research Treatment Clinical Development 52

On Medicine

MARCH 8, 2023

The POTION project The overall objective of POTION is to delve deeper into the understanding of how the sense of smell influences human social interaction. The project will investigate social interaction, combining new knowledge about the chemical composition of human social chemosignals with a new smell-based technology designed to drive social behavior.

Treatment 52

Treatment Trials Regulations Therapies 52

Drug Discovery World

MARCH 9, 2023

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Dr Simon Fricker, who just last year was made Chief Development Officer of PepperBio to support the company’s next phase of growth and guide the strategic expansion of Pepper’s oncology pipeline.

Science 130

Science Drugs Drug Development 130

Drug Patent Watch

MARCH 10, 2023

Annual Drug Patent Expirations for DYANAVEL+XR+15 Dyanavel Xr 15 is a drug marketed by Tris Pharma Inc and is included in one NDA. It is available from one supplier. There… The post New patent for Tris Pharma drug DYANAVEL XR 15 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Labcorp Drug Development

MARCH 8, 2023

When it comes to discoveries in oncology, cancer patients can’t wait, which means neither can you. At Labcorp Preclinical Oncology, we understand there are many steps, phases and regulations to wade through to get to a lead drug candidate—all while time is of the utmost importance. We are excited to … The post Program management services are now offered as part of Labcorp’s Preclinical Oncology Services appeared first on Insights From Our Labs to Yours.

Regulations 52

Regulations Drugs 52

DrugBank

MARCH 8, 2023

DrugBank's deep pool of drug knowledge can be used for everything from AI in drug discovery to In Silico, Precision Medicine, and so much more. We’ve intentionally structured our knowledgebase and datasets as a means of delivering specific and empowering insights that are usable for the full range of our users. To make sure you're getting the most out of DrugBank we've created a series of Data Implementation Guides.

Drugs 52

Drugs 52

Drug Discovery World

MARCH 9, 2023

A new 11,800 square foot specialised life sciences laboratory will be built in the roof space of The Francis Crick Institute in London, UK. The first partners to occupy the space are MSD, having agreed a three-year lease on the new Skylab. Building will commence this spring and MSD scientists are expected to move into the space as early as April 2024.

Nurses 130

Nurses Laboratories Science Disease 130

Drug Patent Watch

MARCH 10, 2023

Annual Drug Patent Expirations for DYANAVEL+XR+20 Dyanavel Xr 20 is a drug marketed by Tris Pharma Inc and is included in one NDA. It is available from one supplier. There… The post New patent for Tris Pharma drug DYANAVEL XR 20 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Cytel

MARCH 7, 2023

Grammati Sarri was recently interviewed by Inside Precision Medicine for “Improving Health Equity Starts with Real-World Evidence.” To read the interview, click here. Health inequalities are an enduring issue that can be exacerbated by clinical trial recruitment that does not reflect the heterogeneous patient groups most likely to use these technologies when approved in clinical practice.

Clinical Trials 52

Clinical Trials Trials Research Clinical Development 52

Covalent Modifiers

MARCH 7, 2023

Rajaiah Pergu, Veronika M. Shoba, Santosh K. Chaudhary, Dhanushka N. P. Munkanatta Godage, Arghya Deb, Santanu Singha, Uttam Dhawa, Viktoriya Anokhina, Sameek Singh, Sachini U. Siriwardena, Amit Choudhary bioRxiv 2023.03.05.531183; doi: [link] Chimeric small molecules that induce post-translational modification (PTM) on a target protein by bringing it in proximity to a PTM-inducing enzyme are furnishing novel modalities to perturb protein function.

Small Molecule 52

Small Molecule Drugs 52

Drug Discovery World

MARCH 9, 2023

This latest eBook sponsored by Bethyl Laboratories/Fortis Life Science features expert opinions on how imaging technologies are informing drug discovery and bringing more insight into treating diseases. Download this exclusive eBook to learn more about: The importance of imaging innovations in the fight against cancer How magnetic resonance imaging (MRI) is a useful tool throughout the drug development process The vast use-cases of imaging technologies throughout the pharmaceutical industry The

Laboratories 130

Laboratories Drugs Drug Development Pharmaceuticals 130

Drug Patent Watch

MARCH 10, 2023

Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. It is available from one supplier. There are ten patents… The post New patent for Deciphera Pharms drug QINLOCK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Sygnature Discovery

MARCH 7, 2023

Sygnature Discovery, the global integrated drug discovery company, has unveiled a new platform that facilitates the combinational high-throughput assembly and review of molecular degraders ( CHARMED ), in response to a sustained rise in demand for its multi-disciplinary expertise. What is the CHARMED platform? Developed in-house at Sygnature Discovery, CHARMED is a technology platform designed to accelerate and support early-stage targeted protein degradation (TPD) programmes.

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Drugs 52